Novo Nordisk's Awiqli Approval Reshapes Basal Insulin Market
Event summary
- Novo Nordisk received FDA approval for Awiqli® (insulin icodec-abae), a once-weekly basal insulin for adults with type 2 diabetes.
- Awiqli® is the first and only once-weekly basal insulin available in the US, reducing injections from daily to weekly.
- Clinical trials (ONWARDS program, ~2,680 patients) demonstrated efficacy in reducing A1C and a safety profile consistent with existing basal insulins.
- Awiqli® is approved in the US, EU, and 13 additional countries, with market-specific indications for diabetes.
- The drug will be available nationwide in the US in the coming months.
The big picture
Novo Nordisk's Awiqli represents a significant shift in basal insulin therapy, addressing a long-standing patient need for increased convenience and adherence. The approval underscores the growing focus on personalized medicine and patient-centric treatment approaches within the diabetes care market. While the basal insulin market is substantial, Awiqli's unique weekly dosing offers a differentiated value proposition that could capture a significant share, potentially disrupting existing treatment paradigms.
What we're watching
- Adoption Rate
- The speed of Awiqli’s adoption will depend on physician and patient acceptance of the weekly dosing regimen, particularly given the established daily insulin landscape.
- Competitive Response
- Other insulin manufacturers will likely accelerate their own development of alternative dosing options to counter Awiqli’s market advantage.
- Reimbursement
- The success of Awiqli will hinge on favorable reimbursement policies from payers, which will determine patient access and overall market penetration.
Related topics